Last reviewed · How we verify
Saw Palmetto - weeks 24 - 48
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to benign prostatic hyperplasia (BPH).
Saw palmetto may inhibit the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to benign prostatic hyperplasia (BPH). Used for Benign prostatic hyperplasia (BPH).
At a glance
| Generic name | Saw Palmetto - weeks 24 - 48 |
|---|---|
| Sponsor | University of Alabama at Birmingham |
| Drug class | Phytotherapeutic |
| Target | 5-alpha-reductase |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
The exact mechanism of saw palmetto's effects on BPH is unclear, but it may involve the inhibition of 5-alpha-reductase, an enzyme responsible for converting testosterone to DHT. This could potentially slow the growth of prostate tissue and alleviate symptoms of BPH.
Approved indications
- Benign prostatic hyperplasia (BPH)
Common side effects
- Gastrointestinal upset
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Saw Palmetto - weeks 24 - 48 CI brief — competitive landscape report
- Saw Palmetto - weeks 24 - 48 updates RSS · CI watch RSS
- University of Alabama at Birmingham portfolio CI